These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30186134)

  • 21. Autoimmune polyradiculitis due to combination immunotherapy with ipilimumab and nivolumab for the treatment of metastatic melanoma.
    Lasocki A; Smith K
    J Clin Neurosci; 2020 Apr; 74():240-241. PubMed ID: 31983645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management.
    Sznol M; Postow MA; Davies MJ; Pavlick AC; Plimack ER; Shaheen M; Veloski C; Robert C
    Cancer Treat Rev; 2017 Jul; 58():70-76. PubMed ID: 28689073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma.
    Carreau NA; Pavlick AC
    Future Oncol; 2019 Feb; 15(4):349-358. PubMed ID: 30334646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination Nivolumab/Ipilimumab Immunotherapy For Melanoma With Subsequent Unexpected Cardiac Arrest: A Case Report and Review of Literature.
    Khoury ZH; Hausner PF; Idzik-Starr CL; Frykenberg MRA; Brooks JK; Dyalram D; Basile JR; Younis RH
    J Immunother; 2019 Oct; 42(8):313-317. PubMed ID: 31206394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature.
    Spain L; Walls G; Julve M; O'Meara K; Schmid T; Kalaitzaki E; Turajlic S; Gore M; Rees J; Larkin J
    Ann Oncol; 2017 Feb; 28(2):377-385. PubMed ID: 28426103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.
    Barbee MS; Ogunniyi A; Horvat TZ; Dang TO
    Ann Pharmacother; 2015 Aug; 49(8):907-37. PubMed ID: 25991832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autoimmune Bell's Palsy Following Immunotherapy For Metastatic Melanoma: A Report of 2 Cases.
    Zieman D; Frankel AE
    J Immunother; 2019 Oct; 42(8):318-320. PubMed ID: 31318723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
    Yoshino K; Nakayama T; Ito A; Sato E; Kitano S
    BMC Cancer; 2019 Oct; 19(1):1019. PubMed ID: 31664934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Case of Erythema Multiforme Major Developed after Sequential Use of Two Immune Checkpoint Inhibitors, Nivolumab and Ipilimumab, for Advanced Melanoma: Possible Implication of Synergistic and/or Complementary Immunomodulatory Effects.
    Utsunomiya A; Oyama N; Iino S; Baba N; Chino T; Utsunomiya N; Hasegawa M
    Case Rep Dermatol; 2018; 10(1):1-6. PubMed ID: 29515387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors).
    Bourke JM; O'Sullivan M; Khattak MA
    Med J Aust; 2016 Nov; 205(9):418-424. PubMed ID: 27809739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What do we know about cancer immunotherapy? Long-term survival and immune-related adverse events.
    Miranda Poma J; Ostios Garcia L; Villamayor Sanchez J; D'errico G
    Allergol Immunopathol (Madr); 2019; 47(3):303-308. PubMed ID: 29983240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy-Review of the Literature and Future Outlook.
    Möhn N; Beutel G; Gutzmer R; Ivanyi P; Satzger I; Skripuletz T
    J Clin Med; 2019 Oct; 8(11):. PubMed ID: 31653079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population.
    Sattar J; Kartolo A; Hopman WM; Lakoff JM; Baetz T
    J Geriatr Oncol; 2019 May; 10(3):411-414. PubMed ID: 30104155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.
    Scott ES; Long GV; Guminski A; Clifton-Bligh RJ; Menzies AM; Tsang VH
    Eur J Endocrinol; 2018 Feb; 178(2):173-180. PubMed ID: 29187509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.
    Blake Z; Marks DK; Gartrell RD; Hart T; Horton P; Cheng SK; Taback B; Horst BA; Saenger YM
    J Immunother Cancer; 2018 Apr; 6(1):25. PubMed ID: 29622046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fatal myositis and spontaneous haematoma induced by combined immune checkpoint inhibitor treatment in a patient with pancreatic adenocarcinoma.
    Liu Y; Liu Z; Zeng X; Bai C; Chen L; Lin S; Tian X
    BMC Cancer; 2019 Dec; 19(1):1193. PubMed ID: 31805889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy and Management of Adverse Events of Ipilimumab Including Combination Therapy with Nivolumab].
    Uhara H; Itakura E
    Gan To Kagaku Ryoho; 2019 Jun; 46(6):1017-1026. PubMed ID: 31273168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases.
    Garcia CA; El-Ali A; Rath TJ; Contis LC; Gorantla V; Drappatz J; Davar D
    J Immunother Cancer; 2018 Aug; 6(1):83. PubMed ID: 30170622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer.
    Williams TJ; Benavides DR; Patrice KA; Dalmau JO; de Ávila AL; Le DT; Lipson EJ; Probasco JC; Mowry EM
    JAMA Neurol; 2016 Aug; 73(8):928-33. PubMed ID: 27271951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.
    Hryniewicki AT; Wang C; Shatsky RA; Coyne CJ
    J Emerg Med; 2018 Oct; 55(4):489-502. PubMed ID: 30120013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.